Intraoperative Esketamine and Postpartum Depression Among Women With Cesarean Delivery: A Randomized Clinical Trial
Primary resultResult — go to the resultRelative risk 0.53 95% CI 0.30–0.93Authors' conclusion
This randomized clinical trial demonstrated esketamine's advantage in reducing the incidence of PPD at 6 weeks post partum in patients who underwent cesarean delivery.
Study context
- Population
- Pregnant patients admitted for cesarean delivery, excluding intellectual dysfunction or contraindications to esketamine; Chongqing, China, March 2023 to February 2024
- Participants
- 308 patients
- Comparison
- Intraoperative esketamine 0.25 mg/kg vs saline
- Esketaminen = 154
- Controln = 154reference
- Primary endpoint
- Incidence of PPD (Edinburgh Postnatal Depression Scale)
- Follow-up
- 6 weeks post partum
Methodological detailssingle-centre, 1:1 randomisation, placebo (saline)-controlled
- Single-centre
- 1:1 randomisation
- Placebo (saline)-controlled
Primary result
As reported in the abstract
Relative risk
0.53
95% CI 0.30–0.93
P = 0.02
Events by treatment group
Esketamine vs Control
RR 0.53 (95% CI 0.30–0.93); P = 0.02
Original publication
Intraoperative Esketamine and Postpartum Depression Among Women With Cesarean Delivery: A Randomized Clinical Trial. JAMA Netw Open. Published 3 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →